Abstract

Despite underrepresentation of women in cardiac resynchronization therapy studies, it has been conclusively shown that women demonstrate greater benefit than men in functional status, reverse cardiac remodeling, and survival and female gender remains an independent predictor of greater response to cardiac resynchronization therapy after adjustment for various other factors. Eligible female patients are less likely to receive this beneficial therapy and various performance enhancement initiatives can reduce this gender-based disparity with favorable outcomes.